Circle Pharma, a South San Francisco, CA-based macrocycle drug discovery, raised over $4.5M in Series A funding.
The round was led by Mission Bay Capital, with participation from Pfizer Inc. (NYSE:PFE), ShangPharma Investment Group, Ltd. and a group of individual investors. In connection with the financing, Walter H. Moos, Ph.D. of ShangPharma, joined Circle Board’s of Directors.
The company intends to use the funds to advance its therapeutic pipeline, which is focused on intracellular protein-protein interactions that are key drivers in oncogenic pathways.
Founded by Prof. Matthew P. Jacobson (Chair of the Dept. of Pharmaceutical Chemistry at UC San Francisco and co-founder of Global Blood Therapeutics (NASDAQ: GBT) and Relay Therapeutics) and Prof. R. Scott Lokey (Dept. of Chemistry and Biochemistry, UC Santa Cruz and director of the UCSC Chemical Screening Center) and led by David J. Earp, J.D., Ph.D., president and CEO, Circle Pharma leverages its macrocycle development platform to develop drugs to treat a wide range of serious diseases initially focusing on intracellular protein-protein interactions that are key drivers in cancer.
The company is also building a physical library of cell-permeable macrocycles to augment its computational design tools, which will later be available to collaboration partners.